Persistent positron emission tomography positivity secondary to benign histiocytic proliferation after treatment of Hodgkin lymphoma

Chumsri, Saranya; Tummala, Mohan K.; Khna, Ahsan M.; Zhao, X. Frank; Rapoport, Aaron P.

doi:10.1080/10428190601140058

Cited by 6 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 3 details the clinicopathologic and radiologic results of 23 patients previously reported in the literature [13][14][15][16][17][18][19][20][21][22][23]. In summary, PHP was identified by PET/CT, CT only or physical examination.…”

Section: Resultsmentioning

confidence: 99%

“…There has been inconsistency in the naming of this phenomenon (i.e., xanthomatous pseudotumor and benign histiocytic proliferation with xanthomatous changes) and the clinical setting in which it is found. We favor the term post-chemotherapy histiocyte-rich pseudotumor (PHP) proposed by Chandra et al [14] to better describe these lesions and their clinical implications [13,15]. Here, we report a series of 5 patients diagnosed with non-Hodgkin lymphoma who developed a PHP and review the literature.…”

Section: Introductionmentioning

confidence: 99%

“…There are rare reports and one case series in the literature where biopsies of a residual mass with or without FDG avidity in lymphoma patients demonstrated benign histiocyte proliferations [13][14][15][16][17]. There has been inconsistency in the naming of this phenomenon (i.e., xanthomatous pseudotumor and benign histiocytic proliferation with xanthomatous changes) and the clinical setting in which it is found.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Post-Chemotherapy Histiocyte-Rich Pseudotumors: Radiologic and Endoscopic Mimics of Residual Lymphoma

et al. 2021

View full text Add to dashboard Cite

Development of post-chemotherapy histiocyte-rich pseudotumor (PHP) is an underrecognized event following therapy in lymphoma patients and may mimic residual tumor using current therapy monitoring protocols. We report a series of 5 patients with PHP along with a review of the literature. In our series, we describe 3 patients with persistent hypermetabolic masses by positron emission tomography-computed tomography, one with persistent terminal ileal nodules on endoscopy, and one with bone marrow involvement, a site not associated with mass-like disease. Twenty-three patients with long-term follow-up were identified from our series and review of the literature. Forty-four percent of patients received additional therapy, and only 4% of patients died of lymphoma. This study illustrates that PHPs are not identified using current lymphoma therapy monitoring algorithms and may result in overtreatment with risk for additional therapy-related complications. The need for confirmatory tissue biopsy in this setting is recommended.

show abstract